Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.
N Engl J MedSep 24, 2026
Matthew J Frigault, Binod Dhakal, Andrzej J Jakubowiak et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 1 multicenter study evaluated the safety and efficacy of anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR T-cell therapy, in 40 patients with relapsed or refractory multiple myeloma. Results showed that 100% of patients responded, with 79% achieving a complete response. Adverse events were common, but severe cytokine release syndrome and neurotoxicity were rare.
Key findings
- All 38 treated patients had a response, with 79% achieving a complete response.
- The 24-month progression-free survival rate was 57%, and the median progression-free survival was 30.2 months.
- 97% of patients experienced an adverse event, with 94% having cytokine release syndrome of grade 1 or 2.
Why it matters
The study highlights the potential of anito-cel as an effective treatment option for patients with heavily pretreated relapsed or refractory multiple myeloma, demonstrating high response rates and manageable safety profiles.